<DOC>
	<DOCNO>NCT00005090</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining chemotherapy peripheral stem cell transplantation may allow doctor give high dos chemotherapy drug kill tumor cell . It yet know combination chemotherapy effective without peripheral stem cell transplantation treat Hodgkin 's Disease . PURPOSE : Randomized phase III trial compare effectiveness combination chemotherapy without peripheral stem cell transplantation treat men stage III stage IV Hodgkin 's disease .</brief_summary>
	<brief_title>S9901 Combination Chemotherapy With Without Peripheral Stem Cell Transplantation Treating Men With Stage III Stage IV Hodgkin 's Disease</brief_title>
	<detailed_description>OBJECTIVES : - Compare progression-free overall survival patient stage III IV Hodgkin 's disease treat doxorubicin , bleomycin , vinblastine , dacarbazine without autologous peripheral blood stem cell transplantation high-dose chemotherapy . - Compare toxic effect treatment regimens patient . OUTLINE : This randomize , multicenter study . Patients stratify accord number poor prognostic factor ( 3 vs 4 v 5 ) stage disease ( III v IV ) . Patients receive induction chemotherapy consist doxorubicin IV 5 minute , bleomycin IV 10 minute , vinblastine IV 5 minute , dacarbazine IV 15-30 minute day 1 15 . Treatment repeat every 28 day 5 course absence disease progression unacceptable toxicity . Patients show least partial response fifth course induction chemotherapy whose blood count recover randomize 1 2 treatment arm . - Arm I : Patients receive 3 additional course induction chemotherapy total 8 course . - Arm II : Patients receive 1 additional course induction chemotherapy follow stem cell collection . Patients receive high-dose chemotherapy carmustine IV 2 hour day -6 -4 , etoposide IV 4 hour day -4 , cyclophosphamide IV day -2 . Patients undergo autologous peripheral blood stem cell transplantation day 0 . Patients follow 60 day , every 3 month 1 year , every 6 month 2 year , annually thereafter . PROJECTED ACCRUAL : Approximately 460 patient accrue study within 4 year .</detailed_description>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Bleomycin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm stage III IV Hodgkin 's disease least 3 follow characteristic : Albumin le 4.0 mg/dL Hemoglobin le 10.5 g/dL Leukocytosis least 15,000/mm^3 Lymphocytopenia less 600/mm^3 less 8 % total WBC Male sex At least 45 year age Stage IV disease Bidimensionally measurable disease Bilateral unilateral bone marrow aspiration biopsy perform within 42 day study Negative chest xray within 42 day study OR Chest xray perform within 28 day study Negative CT scan thorax , abdomen , pelvis within 42 day study OR CT scan thorax , abdomen , pelvis perform within 28 day study No history lymphoma , myelodyplastic syndrome , leukemia No CNS involvement Hodgkin 's disease PATIENT CHARACTERISTICS : Age : 15 65 Performance status : Zubrod 01 Life expectancy : Not specify Hematopoietic : See Disease Characteristics Hepatic : See Disease Characteristics Bilirubin great 1.5 time upper limit normal ( ULN ) ( unless elevation due liver infiltration Hodgkin 's disease ) Lymphomarelated hepatic dysfunction allow Renal : Creatinine great 2.0 time ULN Creatinine clearance least 60 mL/min Lymphomarelated renal dysfunction allow Cardiovascular : No coronary artery disease , cardiomyopathy , congestive heart failure , arrhythmias require therapy Ejection fraction normal No significant EKG abnormality suggest active cardiac disease Pulmonary : Corrected DLCO least 60 % OR FEV1 least 60 % predict Other : Not pregnant nursing Fertile patient must use effective contraception No HIV AIDS No prior malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer No active bacterial , fungal , viral infection* Afebrile 3 consecutive days* NOTE : *Prior randomization portion study PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy Hodgkin 's disease except single course ABVD ( doxorubicin , bleomycin , vinblastine , dacarbazine ) within 35 day study Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy Hodgkin 's disease Surgery : Not specify Other : At least 3 day since prior antibiotic , antifungal , antiviral ( except prophylactic therapy fever associate underlying lymphoma ) ( randomization portion study )</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>stage III adult Hodgkin lymphoma</keyword>
	<keyword>stage IV adult Hodgkin lymphoma</keyword>
</DOC>